Transport properties of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in the rat choroid plexus

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 7, 1997, Pages 611-622

  Takasawa, Katsuko ^a   Suzuki, Hiroshi ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

2',3' dideoxyinosine; 3' azido 3 ' deoxythymidine; Choroid plexus; Organic anion; Transport

Indexed keywords

4 CHLOROMERCURIBENZOIC ACID; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; DIDANOSINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ACTIVE TRANSPORT; ANIMAL TISSUE; ARTICLE; BRUSH BORDER; CEREBROSPINAL FLUID; CHOROID PLEXUS; DRUG TRANSPORT; MALE; NONHUMAN; RAT;

4-CHLOROMERCURIBENZENESULFONATE; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; CHLOROMERCURIBENZOATES; CHOROID PLEXUS; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; P-CHLOROMERCURIBENZOIC ACID; PENICILLIN G; RATS; RATS, WISTAR; ROTENONE; SULFHYDRYL REAGENTS; TRITIUM; UNCOUPLING AGENTS; ZIDOVUDINE;

EID: 0030850392     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199710)18:7<611::AID-BDD45>3.0.CO;2-2     Document Type: Article

References (37)

1. H. Mitsuya, K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. Nusinoff-Lehrmann, R. C. Gallo, D. Bolognesi, D. W. Barry and S. Broder. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent thai inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III lymphadenopathy-associated virus in vitro. Proc. Nat. Acad. Sci. USA, 82, 7096-7100(1985).
2. H. Mitsuya and S. Broder, Inhibition of the in vitro infectivity and cytopathic effect of human Tlymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′, 3′dideoxynuclcosides. Proc. Nat. Acad. Sci. USA, 83, 1911-1915 (1986).
3. Z. Hao, D. A. Cooncy, N. R. Martman, C. F. Perno, A Fndland, A. L. de Vico, M. G. Sarngadharan, S. Broder and D. G. Johns. Factors determining the activity of 2′,3′ dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol., 34, 431-435 (1988).
4. M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. Phil and D. King. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med., 317. 185-191 (1987).
5. R. Yarchoan, C. F. Perno, R. V. Thomas, R. W. Klecker, J.-P. Allain, R. J. Wills, N. McAtee, M. A. Fischl, R. Dubinsky, M. C. McNeely, M. Mitsuya, J. M. Pluda, T. J. Lawley, M. Leuthcr. B. Safai, J. M. Collins, C. E. Myers and S. Broder, Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1, 76-81 (1988).
6. R. Yarchoan, H. Mitsuya, J. M. Pluda, K. S. Marczyk, R. V. Thomas, N. R. Hartman, P. Brouwers, C.-F. Perno, J.-P. Allain, D. G. Johns and S. Broder, The National Cancer Institute phase I study of 2′.,3′-dideoxyinosinc administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev. Infect. Dis., 12. S522-S533 (1990).
7. K. M. Butler, R. N. Husson, F. M. Balis, P. Brouwers, J. Eddy, D. El-Amm, J. Gress, M. Hawkins, P. Jarosinski, H. Moss, D. Poplack, S. Santucrocc, D. Venzon, L. Wiener, P. Wollers and P. A. Pizzo. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N. Engl. J. Med., 324. 137-144 (1991).
8. X. R. Yarchoan, G. Berg, P. Brouwers, M. A. Fischl, A. R. Spitzer, A. Wichman, J. Grafman, R. V. Thomas, B. Safai, A. Brunetti, C. F. Perno, P. J. Schmidt, S. M. Larson, C. E. Myers and S. Broder. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1. 132-135 (1987).
9. P. A. Pizzo, J. Eddy, J. Falloon, F. M. Balls, R. F. Murphy, H. Moss, P. Wolters, P. Brouwers, P. Jarosinski, M. Rubin, S. Broder, R. Yarchoan, A. Brunetti, M. Maha, S. NusinofT-Lehrman and D. G. Poplack, Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N. Engl. J. Med., 319, 889-896 (1988).
10. G. M. Shaw, M. E. Harper, B. H. Hahn, L. G. Epstein, D. C. Gajdusek, R. W. Price, B. A. Navia, C. K. Petito, C. J. O'Hara, J. E. Groopman, E.-S Cho, J. M. Oleske, F. Wong-Staal and R. C. Gallo, HTLV-III infection in brains of children and adults with AIDS enccphalopathy. Science, 227, 177-182 (1985).
11. S. Koenig, H. E. Gendelman, J. M. Orenstein, M. C. dal Canto, G. H. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin and A. S. Fauci, Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science, 233. 1089-1093 (1986).
12. R. W. Price, B. Brew. J. Sidlis, M. Rosenblum, A. C. Scheck and P. Cleary. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science, 239. 586-592 (1988).
13. R. E. Galinsky, B. L. Hoesterey and B. D. Anderson, Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci., 47, 781-788 (1990).
14. R. E. Galinsky, K. K. Flaharty, B. L. Hoesterey and B. D. Anderson, Probenecid enhances central nervous system uptake of 2′, 3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J. Pharmacol. Exp. Ther., 257, 972-978 (1991).
15. M. A. Hedaya and R. J. Sawchuk, Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm. Sci., 78, 716-722 (1989).
16. R. J. Sawchuk and M. A. Hedaya, Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm. Res., 7, 332-338 (1990).
17. S. L. Wong, K. van Belle and R. J. Sawchuk, Distributional transport kinetics of zidovudine between plasma and brain extracellular fluidzcerebrospinal fluid in the rabbit: investigation of the inhbitory effect of probenecid utilizing microdialysis. J. Pharmacol. Exp. Ther., 264, 899-909 (1993)
18. R. Masereeum, U. Jaehde, M. W. E. Langemeijer, A. G. de Boer and D. D. Breimer, In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res., 11, 324-330 (1994).
19. R. Spector and A. V. Lorenzo, Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. J. Clin. Invest., 54, 316-325 (1974)
20. R. Spector and A. V. Lorenzo, The effects of salicylate and probenecid on the cerebrospinal fluid transport of penicillin, aminosalicylic acid and iodide. J. Pharmacol. Exp. Ther., 188, 55-65(1974).
21. H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Transport of benzylpenicillin by the rat choroid plexus in vitro. J. Pharmacol. Exp. Ther., 242. 660-665 (1987).
22. M. Ogawa, H. Suzuki, Y. Sawada, M. Hanano and Y. Sugiyama, Kinetics of active efflux via choroid plexus of β-lactam antibiotics from the CSF into the circulation. Am. J. Physiol., 266, R392-R399 (1994)
23. H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Anion exchanger mediates benzylpenicillin transport in rat choroid plexus. J. Pharmacol. Exp. Ther., 243, 1147-1152 (1987).
24. H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga, M. Hanano and R. Spector, Transport of imipenem, a novel carbapcnem antibiotic, in the rat central nervous system. J. Pharmacol. Exp. Ther., 250, 979-984(1989).
25. T. Nohjoh, H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Transport of cefodizime, a novel third generation cephalosporin antibiotic, in isolated rat choroid plexus. J. Pharmacol. Exp. Ther., 250, 324-328 (1989).
26. H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano, Transport of cimetidine by the rat choroid plexus in vitro. J. Pharmacol. Exp. Ther, 239, 927-935 (1986).
27. K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacohio-Dyn. 4, 879-885 (1981).
28. M. Hanano, Nonlinear least square method (NLS). In Pharmacokinetics, M. Hanano (Ed.), Nanzando, Tokyo, 1987, pp. 116-128.
29. P. de Miranda, S. S. Good, R. Yarchoan, R. V. Thomas, M. R. Blum, C. E. Myers and S. Broder. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin. Pharmacol. Ther., 46, 494-499 (1989).
30. J.-Y Chatton, M. Odone, K. Besseghir and F. Roch-Ramel. Renal secretion of 3′-azido-3′deoxythymidine by the rat. J. Pharmacol. Exp. Ther., 255. 140-145 (1990).
31. D. A. Gritliths, S. D. Hall and P. P. Sokol, Interaction of 3′-azido-3′-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles. J Pharmacol. Exp Ther., 257. 149-155 (1991).
32. D. A. Griffiths. S. D. Hall and P. P. Sokol. Effect of 3′-azido-3′-deoxythymidine (AZT) on organic ion transport in rat renal brush border membrane vesicles. J. Pharmacol. Exp. Ther., 260, 128-133 (1992).
33. T. Aiba, Y. Sakurai, S. Tsukada and T. Koizumi, Effects of probenecid and cimetidine on the renal excretion of 3′-azido-3′-deoxythymidine in rats. J. Pharmacol. Exp. Ther., 272. 94-99 (1995).
34. H. Suzuki, Y. Sawada, Y. Sugiyama, T. Iga and M. Hanano. Salurable transport of cimetidine from cerebrospinal fluid to blood in rats. J. Pharmacobio-Dyn., 8. 73-76 (1985).
35. K. M. Cornford, C. P. Diep and W. M. Pardridgc. Blood brain barrier transport of valproic acid. J. Neurochem., 44. 1541-1550 (1985).
36. H. Matsushita, H. Suzuki, Y. Sugiyama, Y. Sawada, T. Iga, Y. Kawaguchi and M. Hanano. Facilitated transport of cefodizime into the rat central nervous system. J. Pharmacol. Exp. Ther., 259, 620-625 (1991).
37. K. H. Dykstra, A. Arya, D. M. Arriola, P. M. Bungay, P. F. Morrison and R. L. Dednck, Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp Ther., 267. 1227-1236 (1993).